CloudMD - President, Karen Adams.
President, Karen Adams.
Source: LinkedIn.
  • CloudMD (DOC) has shared recent cost optimization and operational integration measures
  • These include team consolidations as well as a new product management team
  • Since the start of the year, the company has eliminated C$7.5M in annualized run-rate costs
  • CloudMD’s connected health tech platform services over 5M individuals across North America
  • CloudMD (DOC) is up by 7.41 per cent trading at $0.87 per share

CloudMD (DOC) has shared recent cost optimization and operational integration measures.

These measures include:

  • Integrating MindBeacon’s iCBT solution into CloudMD’s mental health support solutions, providing assessment and treatment options for mild, moderate and chronic conditions
  • Streamlining and consolidating key operational functions across finance, IT, human resources, marketing and sales, and the executive level, as well as leveraging industry leading talent to drive innovation and retention
  • Strengthening digital health solutions by creating a new product management team focused on innovation
  • The company is also focused on cross-sell revenue synergies through its health ecosystem

Since the start of the year, CloudMD has eliminated C$7.5M in annualized run-rate costs. It expects to realize the full benefit of these savings in Q2 2022.

“The focus is on delivering the product vision, while ensuring we have the operating model and capabilities to deliver profitable growth,” stated Karen Adams, President of CloudMD. “The actions we are announcing today, and the processes we have introduced, will better align our organization and cost structure to achieve these objectives.”

CloudMD is building a connected health tech platform that addresses all points of a patient’s health care journey. It services over 5M individuals across North America.

CloudMD (DOC) is up by 7.41 per cent trading at $0.87 per share as of 12:06 pm EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

BlackBerry expands AI-powered cybersecurity service

BlackBerry (TSX:BB) releases the new and expanded CylanceMDR, a managed detection and response tool backed by its Cylance AI platform.

Qualcomm stock jumps on Q2 2024 earnings

Qualcomm (NDAQ:QCOM) shares rise nearly 10 per cent early Thursday on better-than-expected adjusted earnings and strong revenue guidance.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.